Halozyme Therapeutics Inc (NASDAQ: HALO) has a price-to-earnings ratio that is above its average at 18.59x. The stock has a 36-month beta value of 1.36. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 3 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for HALO is 122.13M, and at present, short sellers hold a 8.25% of that float. On March 27, 2025, the average trading volume of HALO was 1.37M shares.
HALO) stock’s latest price update
Halozyme Therapeutics Inc (NASDAQ: HALO)’s stock price has gone decline by -1.57 in comparison to its previous close of 64.84, however, the company has experienced a -0.75% decrease in its stock price over the last five trading days. zacks.com reported 2025-03-21 that Whether you’re a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
HALO’s Market Performance
HALO’s stock has fallen by -0.75% in the past week, with a monthly rise of 10.05% and a quarterly rise of 35.90%. The volatility ratio for the week is 2.93% while the volatility levels for the last 30 days are 2.95% for Halozyme Therapeutics Inc. The simple moving average for the past 20 days is 3.55% for HALO’s stock, with a 15.96% simple moving average for the past 200 days.
Analysts’ Opinion of HALO
Many brokerage firms have already submitted their reports for HALO stocks, with Wells Fargo repeating the rating for HALO by listing it as a “Equal Weight.” The predicted price for HALO in the upcoming period, according to Wells Fargo is $62 based on the research report published on October 07, 2024 of the previous year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see HALO reach a price target of $57, previously predicting the price at $52. The rating they have provided for HALO stocks is “Neutral” according to the report published on September 19th, 2024.
Piper Sandler gave a rating of “Neutral” to HALO, setting the target price at $51 in the report published on June 07th of the previous year.
HALO Trading at 8.71% from the 50-Day Moving Average
After a stumble in the market that brought HALO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.30% of loss for the given period.
Volatility was left at 2.95%, however, over the last 30 days, the volatility rate increased by 2.93%, as shares surge +10.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +17.88% upper at present.
During the last 5 trading sessions, HALO fell by -0.75%, which changed the moving average for the period of 200-days by +24.07% in comparison to the 20-day moving average, which settled at $61.63. In addition, Halozyme Therapeutics Inc saw 33.49% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HALO starting from Henderson Jeffrey William, who sale 5,000 shares at the price of $58.69 back on Mar 03 ’25. After this action, Henderson Jeffrey William now owns 33,611 shares of Halozyme Therapeutics Inc, valued at $293,458 using the latest closing price.
LaBarre Michael J., the SVP, CHIEF TECHNICAL OFFICER of Halozyme Therapeutics Inc, sale 10,000 shares at $58.12 during a trade that took place back on Feb 26 ’25, which means that LaBarre Michael J. is holding 175,453 shares at $581,244 based on the most recent closing price.
Stock Fundamentals for HALO
Current profitability levels for the company are sitting at:
- 0.54 for the present operating margin
- 0.81 for the gross margin
The net margin for Halozyme Therapeutics Inc stands at 0.44. The total capital return value is set at 0.29. Equity return is now at value 198.42, with 22.79 for asset returns.
Based on Halozyme Therapeutics Inc (HALO), the company’s capital structure generated 0.81 points at debt to capital in total, while cash flow to debt ratio is standing at 0.32. The debt to equity ratio resting at 4.14. The interest coverage ratio of the stock is 30.48.
Currently, EBITDA for the company is 656.54 million with net debt to EBITDA at 2.15. When we switch over and look at the enterprise to sales, we see a ratio of 9.13. The receivables turnover for the company is 3.29for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.80.
Conclusion
To sum up, Halozyme Therapeutics Inc (HALO) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
